Trials / Completed
CompletedNCT00518219
To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN)
To Compare the Efficacy and Safety of TW vs Valsartan in the MN
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- Nanjing University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy of TW compared to Valsartan in treatment of heavy proteinuria of membranous nephropathy.
Detailed description
Membranous nephropathy with heavy proteinuria have high risks of progressing to CRF. Tripterygium (TW) is a Chinese traditional patent drugs, it can reduce proteinuria of chronic glomerular nephritis,such as IgA nephropathy. So, we designed this randomized, prospective clinical trial to assess the efficacy and safety of TW versus Valsartan in the treatment of heavy proteinuria of MN.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TW | TW,120mg/d |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2009-03-01
- Completion
- 2009-09-01
- First posted
- 2007-08-20
- Last updated
- 2010-05-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00518219. Inclusion in this directory is not an endorsement.